ISSN: 2161-0460

Jornal da doença de Alzheimer e parkinsonismo

Acesso livre

Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Indexado em
  • Índice Copérnico
  • Google Scholar
  • Sherpa Romeu
  • Abra o portão J
  • Genâmica JournalSeek
  • Chaves Acadêmicas
  • JornalTOCs
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Biblioteca de Periódicos Eletrônicos
  • RefSeek
  • Universidade Hamdard
  • EBSCO AZ
  • OCLC – WorldCat
  • Catálogo online SWB
  • Biblioteca Virtual de Biologia (vifabio)
  • Publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • ICMJE
Compartilhe esta página

Abstrato

Dietary Polyphenols as Potential Therapeutics in Alzheimer?s Disease: Pleiotropic Effects and Toxicity Prediction Models

Efstathia Kalli, Vlamos Panayiotis

Individualized nutritional treatment with polyphenols has been proposed in the early stages of Alzheimer’s disease. However, it remains unclear at what doses polyphenols and their metabolites enter the brain tissue and whether they can act at sufficient concentrations. The present review provides useful insights into the multiple modes of actions of selected polyphenols as potential therapeutic tools at the pre-clinical stage of Alzheimer’s disease, as well as their ability to cross the blood-brain barrier and their detrimental effects after high dose consumptions. Several studies proposed flavonoids for their potential value in prevention and treatment of neurodegenerative diseases. The scarcity of clinical data though highlights the need for conducting metabolomics studies and well-designed clinical trials. Prolonged clinical trials with bioinformatics tools are needed to fully elucidate both neuroprotective effects and possible risks from polyphenol consumption at concentrated high doses.